Supriya Lifescience’s Ambernath facility receives WHO GMP certification
With global certification in place, the Ambernath site expands Supriya’s footprint beyond APIs into high-margin formulations
With global certification in place, the Ambernath site expands Supriya’s footprint beyond APIs into high-margin formulations
The Ma’anshan site approval covers pastilles, oral liquids, and powders
This certification validates the plant’s robust capabilities in manufacturing a wide range of sterile dosage forms
This was a full GMP inspection of the entire facility with specific focus on Ondansetron Oral Film drug product
The certification marks a new chapter in Windlas Biotech’s growth trajectory,
Expects to unlock further opportunities in the Moldovan market, contributing anticipated sales of $300,000 in 2025 and approximately $700,000–$800,000 in 2026
This approval reflects company’s unwavering commitment that the quality assurance
The certification underscores Venus Remedies Limited's adherence to stringent quality control measures
Subscribe To Our Newsletter & Stay Updated